Protease inhibitors: Silver bullets for chronic hepatitis C infection?

Cleveland Clinic Journal of Medicine

Volumn 79, Issue 3, 2012, Pages 213-222

  Alkhouri, Naim ^a   Zein, Nizar N ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG DERIVATIVE; MACROGOL DERIVATIVE; N (3 AMINO 1 (CYCLOBUTYLMETHYL) 2,3 DIOXOPROPYL) 3 (2 ((((1,1 DIMETHYLETHYL)AMINO)CARBONYL)AMINO) 3,3 DIMETHYL 1 OXOBUTYL) 6,6 DIMETHYL 3 AZABICYCLO(3.1.0)HEXAN 2 CARBOXAMIDE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; TELAPREVIR;

ARTICLE; CHRONIC DISEASE; DRUG COMBINATION; GENETICS; HEPATITIS C; HUMAN;

ANTIVIRAL AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HEPATITIS C; HUMANS; INTERFERON-ALPHA; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; PROTEASE INHIBITORS; RECOMBINANT PROTEINS;

EID: 84859234858     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79a.11082     Document Type: Article

References (30)

1. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195- 1206.
2. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
3. Jacobson IM, McHutchison JG, Dusheiko G, et al, for the ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-2416.
4. Sherman KE, Flamm SL, Afdhal NH, et al, for the ILLUMINATE Study Team. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
5. Zeuzem S, Andreone P, Pol S, et al, for the REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-2428.
6. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
7. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51:729-733.
8. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002; 36:S30-S34.
9. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36:S47-S56.
10. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
11. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(suppl 1):74-81.
12. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36:S3-S20.
13. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900.
14. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355:2444-2451.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
16. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
17. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.e118.
18. Nielsen SU, Bassendine MF, Burt AD, Bevitt DJ, Toms GL. Charac-terization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004; 85:1497-1507.
19. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39:5-19.
20. Nelson DR. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 2011; 31(suppl 1):53-57.
21. Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53:1742-1751.
22. Monto A, Schooley RT, Lai JC, et al. Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010; 105:989-1004.
23. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009; 53:2129-2132.
24. Cholongitas E, Papatheodoridis GV. Review article: novel therapeutic options for chronic hepatitis C. Aliment Pharmacol Ther 2008; 27:866-884.
25. Naggie S, Patel K, McHutchison J. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. J Antimicrob Chemother 2010; 65:2063-2069.
26. Mir HM, Birerdinc A, Younossi ZM. Monoclonal and polyclonal antibodies against the HCV envelope proteins. Clin Liver Dis 2009; 13:477-486.
27. Birerdinc A, Younossi ZM. Emerging therapies for hepatitis C virus. Expert Opin Emerg Drugs 2010; 15:535-544.
28. Khattab MA. Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol 2009; 15:3472- 3479.
29. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198-201.
30. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.